Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson’s nearly two decades of innovation in the disease area Lead asset shows potential to overcome common types of resistance to treatment in prostate cancer with a precision tumor cell-killing approach Includes novel technology platform capable of developing the next generation of highly targeted oral treatments for multiple solid tumors, including breast and lung cancers
